Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alios BioPharma

Request full access

Biotechnology company developing novel medicines for the treatment of viral diseases

United StatesFounded 2006Biotech & Life Sciences

About Alios BioPharma

Alios BioPharma operated as a clinical-stage biopharmaceutical company with a sharp focus on creating therapies to combat viral diseases. The company was founded in 2008 by Lawrence M. Blatt, PhD, who served as its President and CEO. Dr. Blatt's extensive background in virology and drug development, including his prior role as Chief Scientific Officer at InterMune, Inc., directly shaped Alios's mission to tackle significant unmet medical needs in infectious diseases. His journey reflects a deep-seated commitment to translating scientific research into life-saving treatments, a path that saw him co-founding other biotechs like Aligos Therapeutics and Alveo Technologies after his tenure at Alios.

The company's business was centered on the discovery and development of novel antiviral drugs. Its core asset was a proprietary discovery platform, which combined a chemical library of nucleoside analogs with advanced, virology-based screening systems to identify promising therapeutic candidates. This model involved advancing these candidates through preclinical and clinical trials, with the ultimate goal of securing regulatory approval and commercialization. The company's primary clients would have been patients suffering from specific viral infections, with its business strategy culminating in a high-value exit via acquisition.

A significant achievement for Alios BioPharma was its acquisition by Johnson & Johnson for approximately $1.75 billion in cash, a deal completed in November 2014. Following this transaction, Alios was integrated into Janssen Pharmaceutical Companies, the pharmaceutical division of Johnson & Johnson, to bolster its infectious diseases pipeline. At the time of the acquisition, Alios's leading product candidate was AL-8176, an orally administered antiviral therapy in Phase 2 studies for treating respiratory syncytial virus (RSV) in infants. The portfolio also included promising early-stage compounds intended for the treatment of hepatitis C (HCV), which complemented Janssen's existing efforts in that area.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
20.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Sep 2014 $1.8B — Johnson & Johnson —
SERIES BOther financing Apr 2014 $41M $164M SR One · Roche Venture Fund · Novo Ventures · Novartis Venture Fund —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Alios BioPharma website traffic

Latest recorded traffic for Alios BioPharma is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Alios BioPharma in its local ecosystem

Live from Dealroom

The Alios BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Novo Ventures
  • Novartis Venture Fund
  • Roche Venture Fund
  • Novo Seeds
  • Novo Holdings
  • SR One

Other known investors1 additional known investor

  • Johnson & Johnson
Team profiled 221 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Alios BioPharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Alios BioPharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.